Mechanistic insights into molecular targeting and combined modality therapy for aggressive, localized prostate cancer

21Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Radiation therapy (RT) is one of the mainstay treatments for prostate cancer (PCa). The potentially curative approaches can provide satisfactory results for many patients with non-metastatic PCa; however, a considerable number of individuals may present disease recurrence and die from the disease. Exploiting the rich molecular biology of PCa will provide insights into how the most resistant tumor cells can be eradicated to improve treatment outcomes. Important for this biology-driven individualized treatment is a robust selection procedure. The development of predictive biomarkers for RT efficacy is therefore of utmost importance for a clinically exploitable strategy to achieve tumor-specific radiosensitization. This review highlights the current status and possible opportunities in the modulation of four key processes to enhance radiation response in PCa by targeting the: (1) androgen signaling pathway; (2) hypoxic tumor cells and regions; (3) DNA damage response (DDR) pathway; and (4) abnormal extra-/intracell signaling pathways. In addition, we discuss how and which patients should be selected for biomarker-based clinical trials exploiting and validating these targeted treatment strategies with precision RT to improve cure rates in non-indolent, localized PCa.

Cite

CITATION STYLE

APA

Pra, A. D., Locke, J. A., Borst, G., Supiot, S., & Bristow, R. G. (2016). Mechanistic insights into molecular targeting and combined modality therapy for aggressive, localized prostate cancer. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2016.00024

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free